Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom.

Cirtec has been providing design, development, manufacturing, and product transfer services for the medical device industry. With facilities in Los Gatos, CA and Enfield, CT, the company specializes in outsourced solutions for active implantable devices in the areas of neuromodulation, drug delivery, cardiac rhythm management, ventricular assist, and minimally invasive devices. Companies rely on Cirtec’s expertise throughout the entire development cycle to bring life-enhancing therapies to market

UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

Founded in 1994, Quark devoted its early years to developing its innovative technology platform for identification of novel functional target genes and proteins, the “BiFAR” technology. The basic concept, patented by Quark, of high throughput gene inactivation combined with microarray detection of the functional genes responsible for the occurrence of phenotypes of interest, was at that time revolutionary. With the advent of siRNA technology, Quark's approach is rapidly becoming the technology of choice for functional studies industry-wide. We have applied our BiFAR platform in gene discovery programs in serious diseases with significant unmet medical needs, often in collaboration with large pharmaceutical partners. Today we are harvesting the fruits of the innovative targets and concepts we identified.

Sinopec Yangzi Petrochemical Co. Ltd. manufactures, processes, and sells crude oil and petroleum refined products. Its products can be used in the fields of light industry, textile, electronics, foodstuff processing, automobile, aviation, and modern agriculture. The company was founded in April, 1998 and is headquartered in Nanjing, China.

Syncona is a leading healthcare company focused on investing in and building global leaders in life science. Their vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders. They seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. They take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. They focus on delivering dramatic efficacy for patients in areas of high unmet need. Syncona is aligned with two of the premium charitable funders in UK science, The Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in their business. They make a donation of 0.3% of Net Asset Value to a range of charities each year.

Nuvectra Corp. is a neurostimulation medical device company, which engages in the development and commercialization of neurostimulation technology platform for treatment of various disorders through stimulation of tissues associated with the nervous systems. It operates through Nuvectra segment. The Nuvectra segment is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The company was founded on November 14, 2008 and is headquartered in Plano, TX.

Baiyuete Biotechnology (Shanghai) Co., Ltd., established on 2011-09-01, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Import and export;Technology Import and Export;Offshore trade operation;Import and export agency;trade broker;Domestic trade agent;General Cargo Warehousing Services(Does not contain hazardous chemicals and other items that require approval);food sales(Only sell prepackaged food);Pet food and supplies retail;Pet Food and Supplies Wholesale;General merchandise sales;Cosmetics Wholesale;Cosmetics Retail;Chemical product sales(No licensed chemical products);Sales of Class I Medical Devices;Information Consulting Service(Not including licensing information consulting services);internet sales(Except for products that require a license for sale).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Wuhan Rongshi Pharmaceutical Technology Co., Ltd., established on 2012-08-17, Business scope includes biomedicine,traditional Chinese medicine,Western medicine,medical instruments,Technical research on new biochemical drugs,technology transfer;cosmetic,experimental reagent(Does not contain dangerous goods),Fine Chemicals,Technology development of scientific research equipment,Research,Sales and technical consultation;pesticide,Technical research on veterinary medicine.(In the above-mentioned scope of business, the projects with special provisions of the state shall be operated within the approved period after approval or with the license)

Toshiba Corporation (株式会社東芝 Kabushiki-gaisha Tōshiba, English: /təˈʃiːbə, tɒ-, toʊ-/) is a Japanese multinational conglomerate headquartered in Tokyo, Japan. Its diversified products and services include information technology and communications equipment and systems, electronic components and materials, power systems, industrial and social infrastructure systems, consumer electronics, home appliances, medical equipment, office equipment, as well as lighting and logistics.

Standard Microsystems Corp. is a designer of Smart Mixed-Signal Connectivity solutions. It designs and sells a wide range of silicon-based integrated circuits, which utilize analog and mixed-signal technologies. These solutions are applied to a broad set of technologies, including USB, Ethernet, wireless audio, media oriented systems transport, embedded control, captive sensing, and thermal management. Its primary focus is in the development of application-specific technologies. The company was founded in 1971 and is headquartered in Hauppauge, NY.

Shenzhen Tobacco Industry Co., Ltd., established on 1984-05-05, Business scope includes general business items:,The licensing program is:Cigarette production and national sales;tobacco leaf,Redecured Tobacco,cigarette paper,filter stick,tobacco tow,Purchase of Tobacco Special Machinery.

SiGen developed and demonstrated a core set of leading-edge processes for Silicon-on-Insulator (SOI) wafer fabrication using innovations such as plasma activated bonding and room temperature cleaving. The company completed a pilot production facility in 2000 to demonstrate its technology capabilities. After successfully introducing its technology and completing its first major commercial license in 2004, the Company made the transition to being a fabless IP licensor and equipment provider for its engineered substrate solutions. SiGen is located in San Jose, California and has now moved its R&D wafer IP development lab to its corporate headquarters. SiGen has entered into numerous IP licenses, including equipment suppliers, commercial silicon wafer manufacturers, and other advanced substrate manufacturers. The wafer maker licensees have a total market share of over 45% of the world semiconductor silicon wafer market. The Company expects these semiconductor market licensees to capture at least the same or greater share of the SOI market. With numerous emerging opportunities, SiGen expects to broaden its market applications into the Solar Cell market and thus enable the Company to participate in the high growth segments of four major markets: Semiconductor, Solar, Optoelectronic and Display.

Yangtze Petrochemical Co., Ltd., established on 1998-04-24, The business scope includes crude oil processing,petroleum products,Chemical materials,chemicals,chemical fiber,fuel,Processing of equipment,manufacture,Installation and sales;Chemical Technology Services;engineering architectural design,contract,Supervision consultation;Warehousing and transportation service;Chemical Equipment,Parts procurement service;Equipment detection,Maintenance and Repair Services;Providing services.(All items involving national special control commodities and special examination and approval projects,Operate within the validity period of the license;Where the business scope of the company's branches involves special management projects,Operated by a licensed branch)

Established in 1945, Amorepacific is Korea’s No.1 beauty company and a blue-chip corporation. Amorepacific owns nearly 30 well-known brands and has been developing rapidly worldwide. Amorepacific pays great attention to product research and development through research centers located in Korea, France, Japan and Shanghai, to develop premium and high quality skincare and cosmetics products. The Group chose Hong Kong as a strategic bridgehead for the expansion of its presence across the Greater China region and the rest of the world. Two flagship brands - LANEIGE and Sulwhasoo, were introduced in Hong Kong in 2002 and 2004 respectively. The eponymous luxury brand – AMOREPACIFIC, was introduced in Hong Kong in 2014. In 2015, ETUDE HOUSE, a playful cosmetics brand, made its debut in the territory. In 2018, the Company set foot in the personal care product market, introducing the Group’s legendary hair care brand ‘Ryo’ into Hong Kong.

Ildong Pharmaceutical Co., Ltd. engages in the manufacture and sale of medicines, ingredients for medicines, health supplements and special nutritional products. Its products include vitamins, antibiotics, gastric ulcer medicine, peptic ulcerative agents, and diet pills. The company was founded on August 1, 2016 and is headquartered in Seoul, South Korea.

Greatbatch Ltd. develops and manufactures medical devices and components. It specializes in Cardiac Rhythm Management, Neuromodulation, Vascular and Orthopedics. The company was founded on February 5, 1970 and is headquartered in Clarence, NY.

FANUC Corp. engages in the development, manufacture, sale, and maintenance of computer numerical control (CNC) systems, lasers, robot systems, robomachines, roboshot, robocut and nano robots. It operates through the following divisions: Factory Automation (FA), Robot, and Robomachine. The FA division manufactures CNC systems, CNC servo motors, and lasers. The Robot division markets industrial robots through its subsidiaries. The Robomachine division manufactures robodrill (compact machining centre), roboshot (electric injection molding machine), robocut (wire cut electric discharge machine) and roconsists (ultra precision machine). The company was founded by Seiuemon Inaba in1958 and is headquartered in Minamitsuru, Japan.